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Background Not much is known about glycaemic-control trajectories in childhood-
onset type 2 diabetes (T2D). We investigated characteristics of children and young 
people (CYP) with T2D and inequalities in glycaemic control. 
Methods We studied 747 CYP with T2D, <19 years old in 2009-2016 (from total 
population-based National Paediatric Diabetes Audit [>95% diabetes cases in 
England/Wales]). Linear mixed-effects modelling was used to assess socioeconomic 
and ethnic differences in longitudinal glycated haemoglobin (HbA1c) trajectories 
during four years post-diagnosis (3,326 HbA1c datapoints, mean 4.5 
datapoints/subject). Self-identified ethnicity was grouped into six categories. Index of 
Multiple Deprivation (small area-level deprivation measure) was grouped into SES 
quintiles for analysis.  
Results 58% were non-White, 66% were female and 41% were in the most 
disadvantaged SES quintile. Mean age and HbA1c at diagnosis were 13.4 years and 
68mmol/mol respectively. Following an initial decrease between diagnosis and end 
of year 1 (-15.2mmol/mol 95%CI, -19.2, -11.2), HbA1c trajectories increased between 
years 1 and 3 (10mmol/mol, 7.6, 12.4), followed by slight gradual decrease 
subsequently (-1.6mmol/mol, -2, -1.1). 
Compared to White CYP, Pakistani children had higher HbA1c at diagnosis (13.2 
mmol/mol, 5.6-20.9). During follow-up, mixed-ethnicity and Pakistani CYP had 
poorer glycaemic control. Compared to children in the most disadvantaged quintile, 
those in the most advantaged had lower HbA1c at diagnosis (-6.3mmol, -12.6, -0.1). 
Differences by SES remained during follow-up. Mutual adjustment for SES and 
ethnicity did not substantially alter the above estimates. 




Conclusions About two thirds of children with childhood-onset T2D were non-White, 
female adolescents, just under half of whom live in the most disadvantaged areas of 
England and Wales. Additionally, there are substantial socioeconomic and ethnic 
inequalities in diabetes control.  
 
Keywords: Diabetes Mellitus, Type 2; Glycated Hemoglobin A; Healthcare 










Considerable evidence indicates that children and young people (CYP) from ethnic 
minority groups and more disadvantaged backgrounds are at greater risk for 
childhood-onset type 2 diabetes in high-income countries1-5. Type 2 diabetes 
diagnosed in adolescence presents a different set of challenges for both patient and 
healthcare provider compared to that diagnosed in adulthood because is a relatively 
new phenomenon (increasing in incidence due to the ongoing obesity epidemic) and 
till date both research and healthcare provision in paediatric diabetes has largely 
focused on type 1 diabetes2 2,6. Furthermore, paediatric diabetes centres have 
limited experience in managing type 2 compared to type 1 diabetes, particularly in 
administrating the newer therapies used in adults with type 2 diabetes, many of 
which remain unlicensed in this age group. CYP with this condition are at greater risk 
for future comorbidities and complications compared to those with type 1 
diabetes2,5,7-9. These include renal disease (the most common), retinopathy, 
dyslipidaemia, hypertension, depression and neuropsychiatric disorders and poorer 
pregnancy outcomes which further exacerbate glycaemic control8,10-13. Treatment 
and management of type 2 diabetes is complicated involving treating several 
diseases and there is limited evidence on the efficacy of the currently available few 
drug therapies6. This is further complicated by evidence suggesting that CYP with 
this chronic condition require individually tailored treatments.  
 
Ethnic minorities and those from more deprived backgrounds have an increased risk 
for poorer management of chronic conditions leading to increased risk for associated 
comorbidities14,15. Reasons could include poorer access to healthcare systems, 
cultural/ethnic differences and barriers to managing a chronic condition, genetic 




predisposition to the disease itself or comorbidities commonly associated with it16,17. 
Ethnic minorities and lower socioeconomic status (SES) CYP with type 1 diabetes 
are at increased risk for poorer glycaemic control during long-term follow-up which 
also increases their risk for acute and chronic complications18,19. This could be the 
case in CYP with type 2 diabetes, yet there is very limited evidence on glycaemic 
control trajectories in childhood-onset type 2 diabetes following diagnosis. Most 
longitudinal studies originate from North America and none have been total 
population-based2. Studies thus far have been nationally representative sub-samples 
or regional populations, with small sample sizes and/or follow-up less than 3 years. 
Furthermore there is a lack of comprehensive evidence on social and ethnic 
differences in glycaemic control in a national population-based cohort, which is an 
important gap in the evidence base since type 2 diabetes primarily affects more 
deprived and ethnic minority CYP. Therefore, the aim was to analyse socioeconomic 
and ethnic differences in glycaemic control using a population-based national cohort 
of CYP with type 2 diabetes in England and Wales. 
  






Design, setting and data source 
 
Data for this longitudinal study were obtained from the National Paediatric Diabetes 
Audit (NPDA) for England and Wales. The audit (initiated 2002) reached near 100% 
participation covering all 178 paediatric diabetes clinics in 2012. It is comprehensive 
including demographic and clinical data on almost all CYP <19 years of age with all 
forms of diabetes and treated at specialist paediatric diabetes clinics. This study 
focused on data spanning a period of seven years (2009-10 to 2015-16) but 
excluded data from the 2010-11 audit year which could not be linked due to 
administrative reasons. We excluded data from 2002-2008 due to the small number 
of CYP with type 2 diabetes and the low national coverage during the audit’s initial 
years. The National Institute of Health and Care Excellence (NICE) recommends a 
patient with any form of diabetes be offered integrated healthcare by a 
multidisciplinary team at a clinic, with HbA1c levels, height and weight recorded at 
each visit20. All demographic and clinical parameters are recorded systematically 
across clinics enabling comparison. For this analysis, we derived an incident cohort 
with inclusion criteria comprising a diagnosis of type 2 diagnosis, age<19 years on 
the first day of the audit, a minimum of one visit to a clinic during any audit year and 
valid information on date of diagnosis and sex. 1,053 CYP met the inclusion criteria 
during the study period and were eligible to be included in the study.   
Outcome and independent variables 
Glycaemic control – measured by HbA1c levels – was the main outcome of interest. 
HbA1c values recorded as percentages were converted to mmol/mol using the 
formula: (HbA1c value in percentage-2.15) x 10.929. HbA1c values within the range of 
20 to 200mmol/mol and recorded within an audit year as reported by the clinics to 




the NPDA were considered as valid. All valid HbA1c values recorded for a subject 
during the study period were included in the analysis (i.e. multiple HbA1c datapoints 
recorded for any single individual within an audit were treated independently). As per 
NICE recommendations (prior to 2015), HbA1c values <58mmol/mol and 
≥80mmol/mol were categorised as good and poor control respectively20. 
Independent variables included age at diagnosis, sex, diabetes duration, ethnicity 
and SES. Age at diagnosis was calculated by subtracting the date of birth from the 
date of diagnosis. Duration of diabetes was calculated by subtracting date of 
diabetes diagnosis from the date of clinic visit. BMI was calculated as weight (in 
kilograms) divided by height (in metres) squared. Overweight and obesity in children 
was determined by using age- and sex-specific cut-offs proposed by the International 
Obesity Task Force21. Age and sex appropriate BMI standard deviation scores or Z-
scores were calculated from the UK 1990 growth reference22.   
Patients (or their parents) self-reported their ethnicity using one of fifteen categories 
recommended by the Information Standards Board for Health and Social Care 
(including the option to decline stating their ethnicity, the ‘Not Stated’ category). The 
fifteen ethnic categories were collapsed into six broader groups (listed in 
Supplemental Table 1): White (British, Irish and any other White background), Mixed 
(any form of mixed ethnic background), Asian Pakistani, Asian and ‘other’ 
(comprising subjects of all other Asian backgrounds but mostly South Asian in origin 
and any other ethnic background including Chinese and Arabic), Black (subjects of 
Caribbean and African origin), and ‘Not Stated’. We implemented a two stage 
process while cleaning the ethnicity variable to ensure that each subject had the 
same ethnic group entered throughout follow-up,: First, the last recorded entry for 
ethnicity was used in the analysis (assuming subjects that identify their ethnicity at 




older ages reflect their true choice and data validity and completion is better in the 
most recent years). Second, if there was a discrepancy in the entry for ethnicity 
between the last and previous visits, then the most commonly entered category was 
chosen (for example, if a subject identified as White in all visits, but as Black in the 
final visit, then White was chosen as it was the most commonly entered ethnic 
category).  
Indices of Multiple Deprivation (IMD) 2010 were derived from postcodes for England, 
and the Welsh Indices of Multiple Deprivation 2008 for Wales23. These indicators of 
deprivation of small area of residence were used as a measure of SES. Although the 
two countries use slightly differing indices to define deprivation, adjustment was 
made to align the two techniques24. The IMD is a multidimensional index which 
measures the relative deprivation experienced by an individual living in an area with 
an average of 1,500 individuals. Scores are derived from a weighted combination of 
several indicators across seven distinct domains including income, employment, 
education skills and training, health, barriers to housing and services, living 
environment and crime. IMD rank scores were grouped into quintiles for analysis, 
with the first and fifth quintiles corresponding to the least and most disadvantaged 
respectively.   
Treatment regimen was categorised into diet and exercise, oral hypoglyceamics and 
oral hypoglycaemics plus insulin injections. 
Data analysis 
Associations between ethnicity, SES and other covariates were analysed using 
univariable linear regression or Chi square tests for differences of proportions for 
continuous and categorical variables respectively. Continuous variables are 




presented as mean values with standard deviations and categorical variables as 
frequencies.  
Longitudinal analysis – Longitudinal change in HbA1c trajectories were analysed 
using linear mixed effects modelling (growth curve analysis). This method enables 
comparison of population average HbA1c levels and change over time by 
independent variables (SES, ethnicity and treatment regimen) while controlling for 
covariates. We ran three sets of linear mixed effects models: In set 1, SES was the 
main exposure of interest with subsequent models adjusted for covariates (age at 
diagnosis and sex). In set 2, ethnicity was the main exposure of interest and 
subsequent models were adjusted for covariates including SES. Models in set 3 
were based on a smaller study population not missing data on treatment regimen 
and included models adjusted for all covariates of interest. 
Each set of modelling comprised four models: Model 1: Random intercept only 
(unconditional growth model) to define the intraclass correlation coefficient (ICC); 
Model 2: Random intercept and random slope model (which in each set had a better 
statistical fit and was used in all subsequent models); Model 3: adjusted for our 
primary predictor; SES or ethnicity; and Model 4: additionally adjusted for other 
covariates (sex, age at diagnosis and treatment type). In all models we approximated 
time trends including a cubic term for time since diagnosis (duration in years) as this 
provided a better statistical fit compared to having only linear and quadratic terms. 
We separately assessed whether SES and ethnicity interact with duration on mean 
HbA1c trajectories by testing for interactions between SES/ethnicity and diabetes 
duration. Models included individuals with any amount of HbA1c data up to four years 
following diagnosis (i.e. they could have differ in their follow-up time). Additionally, 
models were restricted to four years follow-up following diagnosis since HbA1c 




datapoints were considerably fewer after this. Model parameters were estimated by 
maximum likelihood and a heterogeneous autoregressive covariance structure was 
used in all models. We used generalized likelihood ratio statistics, −2 log-likelihood 
(−2 LL), Aikake information criterion (AIC), and sample-adjusted Bayesian 
information criterion (BIC) to compare model fit between subsequent nested models, 
and Wald statistics to test hypotheses about model parameters. In all models 
ethnicity, SES, age at diagnosis (continuous) and sex were entered as time-invariant 
predictors whereas treatment regimen was entered as time-variant. 
HbA1c trajectories were plotted at the group level (i.e. SES or ethnicity) to visualise 
model fit and were based on model 4 above (adjusted for all covariates). All statistical 
analyses were conducted using STATA 14 (College Station, TX, USA). 
Sensitivity analysis: We investigated whether subjects excluded due to missing data 
on treatment regimen differed from those included in the models with data on 
treatment regimen. The two groups were compared on all covariates using 
univariable linear regression or chi-squared tests for differences of proportions for 
continuous and categorical variables, respectively. 
 
Ethics 
Ethical approval was not required by the University College London (UCL) Research 
Ethics Committee. The NPDA has section 251 approval granted by the 
Confidentiality Advisory Group to collect patient identifiable information for the 
purpose of audit. For this study all participants were anonymised making them 
unidentifiable. The study is registered with the R&D office, Institute of Child Health, 
UCL, (Project number 14PP08). 
  





Of the 1,053 CYP identified with type 2 diabetes, 306 subjects had missing data on 
various covariates (24 missing data on diabetes duration, 3 missing age at 
diagnosis, 74 missing HbA1c, 11 missing SES and 134 missing ethnicity, 
Supplemental Figure S1). A further 60 subjects only had data 4 years post-diagnosis 
leaving a final study population of 747 CYP (with 3,326 HbA1c datapoints) for our 
primary analysis.  
Models in set 3 adjusted for treatment regimen were based on a sub-sample of 557 
CYP (with 2,851 HbA1c datapoints). There were no significant differences between 
the sub-sample with data on treatment regimen and those excluded because of 
missing data (N=190) when compared on sex, age at diagnosis, SES and duration of 
diabetes. However, we did find significant but minor differences in the distribution of 
ethnic groups between the two populations (for example, the ‘not stated’ and White 
groups had higher proportions with missing data on treatment regimen).  
Tables 1 and 2 summarise cohort characteristics by SES and ethnicity respectively. 
Sixty-seven percent of subjects were female and 71% were obese. Forty one 
percent were from the most disadvantaged SES quintile. Mean age at diagnosis was 
13.4 years. CYP in the least disadvantaged SES quintiles had lower HbA1c levels at 
diagnosis compared to those in the most deprived quintiles but differences were not 
statistically significant (Table 1). Pakistani CYP had a significantly higher median 
SES score compared to White CYP (Table 2) and had the largest proportion of 
subjects in the most deprived SES quintile (64% compared to 37% for White CYP, 
Table 2). There were no significant differences in distribution of proportions of sex, 
overweight/obesity and treatment regimen at diagnosis between ethnic groups. 
Overall, 71% and 20% of subjects were obese and overweight respectively. 14% of 




subjects had poor glycaemic control one year post-diagnosis which increased to 
31% four years post-diagnosis (Tables 1 & 2). 
Longitudinal analysis 
Mean HbA1c at diagnosis (model intercept) for the cohort was 64.9mmol/mol (95% CI 
62.5-67.2). There were significant linear, quadratic and cubic terms for duration of 
diabetes. This implies on average, all subjects experienced a decrease in HbA1c 
levels between diagnosis and one year following diagnosis (negative linear term, -
15.2mmol/mol, Supplemental Figure S2). This was followed by a substantial 
increase between one and three years post-diagnosis (positive quadratic term, 
10.8mmol/mol) and finally a much smaller decrease approximately three years post-
diagnosis (negative cubic term, -1.7mmol/mol) in HbA1c levels.  
CYP from the two least disadvantaged SES quintiles had significantly lower HbA1c at 
diagnosis (-7.2mmol/mol, -13.4, -1 for CYP in the least deprived quintile, Table 3) 
compared to most deprived CYP. A test for interaction between diabetes duration 
and SES was not statistically significant indicating the observed differences in HbA1c 
at diagnosis by SES persisted equally throughout follow-up (Figure 1A). 
Table 4 and Figure 1B show results from modelling ethnic differences in glycaemic 
control. All ethnic minority groups had higher HbA1c at diagnosis compared to White 
CYP but differences were significant only in Pakistani CYP (14.8mmol/mol, 7.2-22.4, 
higher HbA1c). The test for interaction between ethnicity and diabetes duration was 
statistically significant (p=0.004) indicating that ethnic-specific HbA1c trajectories 
varied by time. Adjustment for SES made little difference to the ethnicity-HbA1c 
estimates. During follow-up, the mixed-ethnicity and Pakistani groups (linear 
interaction terms -16.1mmol/mol, -32.2, -0.1 and -27.5mmol/mol, -40.6, -14.3 
respectively, Model 4, Table 4) had substantial and additional decreases in HbA1c 




levels compared to the White group. However, these were offset by large increases 
in HbA1c in the same two groups towards the end of follow-up (positive quadratic 
interaction terms, Model 4, Table 4 and Figure 1B).  
In all regression models, neither sex or age at diagnosis were associated with 
glycaemic control. 
Supplemental Table S2 shows socioeconomic and ethnic effects on glycaemic 
control adjusted for treatment regimen. The previously observed higher HbA1c in 
Pakistani and more disadvantaged  groups were still evident but marginally 
attenuated (Model 4, Supplemental Table S2). Subjects on oral hypoglycaemics and 
insulin injections had significantly higher HbA1c at diagnosis compared to those on 
oral hypoglycaemic only (10.5mmol/mol, 7.6-13.3, Model 4, Supplemental Table 2).  






In England and Wales, CYP with type 2 diabetes from socioeconomically 
disadvantaged areas had significantly higher HbA1c at diagnosis compared to those 
from less disadvantaged areas and differences persisted throughout follow-up. 
Pakistani CYP had significantly higher HbA1c at diagnosis, and both Pakistani and 
mixed-ethnicity CYP had significantly poorer glycaemic control during follow-up. This 
total population study confirms that childhood-onset type 2 diabetes largely affects 
overweight female adolescents from disadvantaged and ethnic minority 
backgrounds.   
 
Longitudinal studies on glycaemic control in childhood-onset type 2 diabetes are 
limited with most studies originating from North America. The two larger studies that 
reported extensively on type 2 diabetes in CYP are the Treatment Options for Type 2 
Diabetes in Adolescent and Youth (TODAY), a randomised control trial (RCT) 
focusing on the efficacy of treatment regimens and the SEARCH for Diabetes in 
Youth study based on a nationally representative sample of subjects from five states 
in the US25,26. Both studies reported higher HbA1c at diagnosis and during follow-up 
in ethnic minority groups. However, comparisons are limited as the TODAY study is 
a RCT which reported that ethnic minorities (Black and Hispanics) were more likely 
to achieve failure (defined as loss of glycaemic control [HbA1c≥9%] over a 5 year-
follow-up without adjustment for SES. The SEARCH study (based on a smaller 
sample of subjects, N=373) primarily reported ethnic differences in HbA1c between 
diagnosis and one year after diagnosis26. Neither study reported HbA1c trajectories 
by SES or ethnicity and both are based on regional or nationally representative 
samples but are not total-population based studies. As expected the ethnic groups 




analysed in these studies are more relevant to the US. Comparisons are further 
limited as the healthcare system in the US is based on the type of insurance 
coverage. Other studies that explored glycaemic control in CYP with type 2 diabetes 
have been much smaller in size, based on regional diabetes registries, with shorter 
follow-up, cross-sectional in design and/or reported HbA1c at specific time points 
such as diagnosis, 1 year after diagnosis or the mean value during follow-up5,27-29. 
The only UK study that reported glycaemic control in CYP with type 2 diabetes was 
based on a smaller sample (N=73) with cases identified via the British Paediatric 
Surveillance Unit (which provides a nationally representative sample)30. 
Comparisons are limited as the study had a short follow-up of one year post-
diagnosis and used the older recommendations for targeted glycaemic control. Mean 
HbA1c at diagnosis and the time course for the observed initial but transient reduction 
in HbA1c between diagnosis and 12 months observed in this study has been reported 
in other smaller studies27,31. This is most likely a response to initial treatment, 
diabetes education and lifestyle changes. However, the rise in HbA1c in all groups in 
the subsequent two years is consistent with evolving beta-cell failure together with 
reduced adherence to treatments and the initial lifestyle changes, together with 
increasing insulin resistance that occurs during adolescence32. This evolution of 
disease processes in type 2 diabetes in this age group and concurrent rise in HbA1c 
from twelve months onwards indicate that either current treatment strategies are 
potentially ineffective, compliance is poor or diabetes presenting in adolescence 
represents a more serious phenotype of the disease compared to that diagnosed in 
adulthood. Additionally, recommended lifestyle changes such as weight reduction 
seem to be limited (as observed by the largely stable BMI trajectory over time since 
diagnosis in this cohort – data not shown). Including BMI in the models did not affect 




the observed ethnicity- and SES-estimates for HbA1c and hence were not reported 
in the final models.  
The main strength of this study is that it describes the natural history of glycaemic 
control in a large well-described population based cohort with >95% of childhood-
onset type 2 diabetes cases in England and Wales. Other strengths include the 
longitudinal prospective population-based design, self-identified ethnicity, follow-up 
from diagnosis onwards, and relatively low missing data on most covariates (sex, 
age at diagnosis, duration and SES with <3% missing data). All data are recorded 
systematically across all paediatric clinics which then submit data to a centralized 
database helping minimize selection bias. Mixed effect modelling allows for the 
inclusion of a large number of data points including subjects with just one HbA1c 
measurement even when the data are ‘unbalanced’ (subjects with differing number 
of data points measured at different time points). 
We were unable to control for family history of diabetes, physical activity and diet 
which could potentially be associated with glycaemic control as this information is not 
collected. The majority of CYP begin transitioning to adult healthcare services from 
around age 16 and as type 2 diabetes is largely diagnosed in adolescence, a follow-
up >4 years is not possible due to the paucity of HbA1c data from the fourth year on. 
The apparent better glycaemic control observed towards the end of follow-up is more 
likely an artefact due to the modelling strategy and paucity of data and should be 
interpreted with caution. Models adjusted for treatment regimen should be 
interpreted with caution as this variable was more likely to be missing during the 
initial years of the audit. However, the reported associations are in the expected 
direction. Lastly, it is possible that the ‘not stated’ ethnic group includes CYP missing 
information on ethnicity. 





There is considerable focus on social determinants of health (SDOH) as a potential 
explanatory factor for both the aetiology of type 2 diabetes and glycaemic control in 
youth. As in our study, others showed substantial proportions (≥40%) of subjects 
come from the most deprived families5,33,34. The conceptual model for SDOH in 
youth with T2D proposes social determinants such as low family income, low 
parental education and higher levels of stress (in parents/caregivers and youth) are 
more prevalent in some ethnic minorities leading to both onset of type 2 diabetes 
and poorer glycaemic control acting via mediators like poorer lifestyle choices, 
healthcare access, family knowledge and coping skills and management of chronic 
diseases35. Attitudes of healthcare providers when treating CYP from diverse ethnic 
and socioeconomic backgrounds could be another explanatory factor though not as 
significant as those above and harder to assess in observational studies like ours. 
Another explanation could be physiological differences between ethnic groups (like 
higher rates of insulin resistance in non-White Europeans). There is evidence for 
higher HbA1c in both type 2 diabetic and non-diabetic people of non-White European 
origin. In several studies, the observed ethnic differences in glycaemic control 
remain after adjustment for a number of social and clinical factors36,37. Additionally, 
inter-individual variation in HbA1c is linked to non-glycaemic factors including sex, 
visceral fat, hormones and differences in biological variation of haemoglobin 
glycation36,38. Thus there is an ongoing debate on whether HbA1c is ideal for 
comparing glycaemic control across ethnic groups and as a diagnostic test for 
diabetes36. Nonetheless, the body of evidence linking poorer glycaemic control with 
higher risk for micro- and macro-vascular complications is undisputed. Our results 
are concerning as they highlight a potential and substantial increase in the burden of 




diabetes-related complications in the near future as poorer glycaemic control starts 
considerably earlier in those with childhood-onset type 2 diabetes. Ethnic minority 
adults with type 2 diabetes are at increased risk for complications including 
cardiovascular disease39.    
In addition to reducing the social inequalities that drive inequalities in child health, 
reducing inequalities in glycaemic control in CYP with type 2 diabetes will require 
substantial interventions beyond the healthcare sector. Whilst it is important to 
address issues post-diagnosis like improving access to healthcare especially for the 
more disadvantaged groups, and closer monitoring of CYP with poorer glycaemic 
control, a focus on population level prevention is also required. As type 2 diabetes is 
a condition closely linked to poorer childhood socio-economic circumstances 
associated with areas with greater deprivation, there is a critical need to address the 
larger issues which can support healthier lifestyles for disadvantaged families and 
subsequently reduce risk for type 2 diabetes. For example, public health 
interventions can be designed to maximise income support for poor families; to make 
healthy food more accessible in disadvantaged neighbourhoods; and to encourage 
physically active lifestyles by improving access to play grounds, recreational areas 
and other facilities, in addition to targeted support for high risk groups, following the 
principle of proportionate universalism40.     
We found substantial evidence for socioeconomic and ethnic inequalities in a large 
population-based cohort of CYP with type 2 diabetes. There is urgent need to further 
investigate which modifiable factors drive these inequalities to prevent diabetes 
associated complications in these groups.    
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Table 1 Characteristics of 747 youth with type 2 diabetes by socioeconomic status and registered 
in the National Paediatric Diabetes Audit (NPDA), England & Wales, 2009-2015. Values are means 
(SD) unless otherwise stated. 





*mean of 2,358 BMI values (for 804 individuals) recorded between diagnosis and 4 years post-diagnosis 
†mean of 3,326 HbA1c values recorded between diagnosis and 4 years post-diagnosis 
‡165 HbA1c values recorded during the first two months following diagnosis 
§Proportions for good or poor glycaemic control for 207 CYP at four years post-diagnosis 
||Proportions for good or poor glycaemic control for 451 CYP at one year post-diagnosis 
¶treatment data available for 198 CYP at diagnosis  
 
  
 Socioeconomic Status (geographic area-level deprivation)   
 Quintile 1 
Most 
advantaged 




        
N (%) 42 (6) 84 (11) 118 (16) 195 (26) 308 (41) 747 (100)  
Females (%) 74 70 72 61 66 67 0.21 
Age at diagnosis (years) 13.6 (1.9) 12.9 (3.3) 13.5 (2.2) 13.7 (2.3) 13.3 (2.2) 13.4 (2.3) 0.71 
Deprivation score 
(median) 
5.3 10.9 17.5 28.5 48.8 30.1  
BMI categorical (%)       0.34 
Overweight  18 11 16 22 21 20  
Obese  68 75 74 71 71 71  
        
BMI Z-score* 2.1 (1.1) 2.7 (1.2) 2.6 (0.9) 2.6 (1) 2.6 (1) 2.6 (1) 0.23 
        
HbA1c (mmol/mol)† 57.7 (21.8) 57.5 (20) 62.7 (24.5) 61.9 (25.7) 65.5 (26.8) 62.9 (25.5) 0.03 
HbA1c (%)† 7.4 (4.1) 7.4 (4) 7.9 (4.4) 7.8 (4.5) 8.1 (4.6) 7.9 (4.5) 0.03 
HbA1c at diagnosis‡ 56.5 (22.8) 64.1 (19.2) 73.1 (26.4) 67.2 (25.7) 68.6 (27.2) 67.9 (25.9) 0.4 
HbA1c at diagnosis‡ (%) 7.3 (4.2) 8 (3.9) 8.8 (4.6) 8.3 (4.5) 8.4 (4.6) 8.4 (4.5) 0.4 
Glycaemic control at end 
of follow-up (%)§ 














 Poor  (≥80mmol/mol) 25 27 28 28 38 31 0.83 
Glycaemic control one 
year post-diagnosis (%)|| 














 Poor  (≥80mmol/mol) 9 12 16 12 16 14 0.85 
        
Treatment regimen at 
diagnosis (%)¶ 
       
Diet &  exercise 21 38 31 40 46 39  
Oral hypoglycaemics 71 62 60 51 44 52  
Oral hypoglycaemics & 
insulin 
7 - 9 9 10 9 0.52 




Table 2 Characteristics of 747 youth with type 2 diabetes by ethnicity and registered in the National Paediatric Diabetes Audit 
(NPDA), England & Wales, 2009-2015. Values are means (SD) unless otherwise stated. 
 Ethnicity   
 White Mixed-
ethnicity 
Asian/Other Pakistani Black Not Stated All P 
N (%) 316 (42) 37 (5) 129 (17) 90 (12) 55 (7) 120 (16) 747 (100)  
Females (%) 71 59 61 66 73 60 67 0.11 
Age at diagnosis 
(years) 
13.3 (2.4) 13.2 (1.6) 13.5 (2.1) 13.4 (2.1) 13.2 (2.5) 13.7 (2.8) 13.4 (2.3) 0.68 
Deprivation score 
(median) 
28 29 30 45 31 26 30  
BMI categorical (%)        NS 
Overweight  12 22 32 20 24 20 19 0.43 
Obese  80 75 56 70 67 71 71  
BMI Z-score* 2.8 (0.1) 2.6 (1) 2.3 (0.9) 2.6 (0.8) 2.7 (0.9) 2.5 (1.1) 2.6 (1) <0.001 
HbA1c (mmol/mol)† 60.2 (22.8) 75.8 (31.6) 60.1 (23.4) 64.4 (25.4) 66.6 (30.1) 65.3 (27.5) 62.8 (25.4) 0.02 
HbA1c (%)† 7.7 (4.2) 9.1 (5) 7.6 (4.3) 8 (4.5) 8.2 (4.9) 8.1 (4.7) 7.9 (4.5) 0.02 
HbA1c at diagnosis‡ 62.4 (22.8) 72.2 (34.5) 66.5 (21.6) 78.1 (30.5) 82.5 (25.9) 69.2 (27.7) 67.7 (25.9) 0.10 
HbA1c at diagnosis‡ (%) 7.9 (4.2) 8.8 (5.3) 8.2 (4.1) 9.3 (4.9) 9.7 (4.5) 8.5 (4.7) 8.3 (4.5) 0.10 
Glycaemic control at 
end of follow-up (%)§ 
















 Poor  (≥80mmol/mol) 30 89 30 32 33 19 31 NA 
Glycaemic control one 
year post-diagnosis 
(%)|| 
















 Poor  (≥80mmol/mol) 13 24 14 11 14 13 14 NA 
         
Proportion in most 
deprived SES quintile 
37 41 43 64 37 36 41 <0.000
1 
Treatment regimen at 
diagnosis (%)¶ 
        




Diet &  exercise 32 67 34 45 33 53 39 0.11 
Oral hypoglycaemics 62 33 47 45 58 38 52  
Oral hypoglycaemics & 
insulin 
6 - 19 10 8 9 9  
*mean of 2,388 BMI values (for 669 individuals) recorded between diagnosis and 4 years post-diagnosis 
†mean of 3,372 HbA1c values recorded between diagnosis and 4 years post-diagnosis 
‡173 HbA1c values recorded during the first two months following diagnosis 
§Proportions for good or poor glycaemic control for 207 CYP at four years post-diagnosis 
||Proportions for good or poor glycaemic control for 459 CYP at one year post-diagnosis 
¶treatment data on 198 CYP 
 




Table 3. Linear mixed-effects models for socioeconomic differences in glycaemic 
control (HbA1c) in 747 children and young people with type 2 diabetes in England 
and Wales, 2008-2015 
 
 Model 1 Model 2 Model 3 Model 4 
Fixed effects Random intercept 
or unconditional 
growth model 
Random intercept + 
random slope model 
Model 2 + 
socioeconomic 
status 
Model 3 + sex & 
age at diagnosis 
Constant/intercept 
(HbA1c mmol/mol) 
64.9 (62.5, 67.2) 64.9 (62.6, 67.2) 66.9 (64, 69.8) 71.9 (60.1, 83.7) 
     
Slope coefficients     
Duration since 
diagnosis (years) 
    
                  Linear -15.2 (-19.2, -11.2) -16.3 (-20.3, -12.3) -16.5 (-20.5, -12.5) -16.4 (-20.4, -12.4) 
                  Quadratic 10      (7.6, 12.4) 10.8  (8.4, 13.2) 10.9  (8.5, 13.3) 10.9  (8.5, 13.3) 
                  Cubic -1.6   (-2, -1.1) -1.7   (-2.1, -1.3) -1.7   (-2.1, -1.3) -1.7   (-2.1, -1.3) 
     
Socioeconomic Status     
Quintile 5 (most 
disadvantaged) 
  Reference Reference 
Quintile 1 (least 
disadvantaged)        
  -7.3 (-13.5, -1.1) -7.2 (-13.4, -1) 
Quintile 2                     -6.1 (-11.1, -1) -6 (-11, -1) 
Quintile 3                    -1.8 (-5.9, 2.4) -1.6 (-5.8, 2.6) 
Quintile 4    -2.5 (-6, 1.0) -2.6 (-6.1, 0.8) 
     
Sex             
                               Male 
    
Reference 
                  Female    -3.2 (-6.4, 0.1) 
     
Age at diagnosis (years)     
0.1 (-0.7, 0.7) 
     
Interclass Correlation 
Coefficient (ICC) 
0.66 0.67 0.67 0.67 
Model fit     
Aikake information 
criterion (AIC) 
28722.03 28491.91 28490.65 28490.92 
Bayesian information 
criterion (BIC) 
28758.69 28540.78 28563.97 28576.45 
-2LL 28710 28474 28466 28462 

















Table 4. Linear mixed-effects models for socioeconomic and ethnic differences in 
glycaemic control (HbA1c) in 747 children and young people with type 2 diabetes in 
England and Wales, 2008-2015 
 Model 1 Model 2 Model 3 Model 4 
Fixed effects Random intercept/or 
unconditional 
growth model 
Random intercept + 
random slope 
model 
Model 2 + 
ethnicity 
Model 3 + 
socioeconomic 




64.9 (62.5, 67.2) 64.9 (62.6, 67.2) 61.7 (58.2, 65.2) 68.8 (56.6, 80.9) 
Slope coefficients     
Duration since 
diagnosis (years) 
    
                  Linear -15.2 (-19.2, -11.2) -16.3 (-20.3, -12.3) -11.3 (-17.3, -5.2) -11.3 (-17.4, -5.3) 
                  Quadratic 10      (7.6, 12.4) 10.8  (8.4, 13.2) 7  (3.4, 10.7) 7  (3.4, 10.7) 
                  Cubic -1.6   (-2, -1.1) -1.7   (-2.1, -1.3) -1   (-1.6, -0.4) -1   (-1.6, -0.4) 
Ethnicity      
White   Reference Reference 
Mixed-ethnicity   8.7   (-1.2, 18.5) 8.1   (-1.7, 18) 
Asian/Other   1.2   (-5.3, 7.8) 0.6   (-6, 7.1) 
Pakistani   14.8 (7.2, 22.4) 13.2 (5.6, 20.9) 
Black   8.8   (-1.4, 19) 8.8   (-1.4, 18.9) 
Not stated   0.7   (-6.3, 7.7) 0.5   (-6.5, 7.6) 
     
Socioeconomic Status     
Quintile 5 (most 
disadvantaged) 
   Reference 
Quintile 1 (least 
disadvantaged)        
   -6.3 (-12.6, -0.1) 
Quintile 2                      -5.8 (-10.9, -0.7) 
Quintile 3                     -1.6 (-5.8, 2.6) 
Quintile 4     -2.7 (-6.2, 0.8) 
     
Sex             
                               Male 
    
Reference 
                  Female    -2.9 (-6.2, 0.3) 
Age at diagnosis (years)     
0.1 (-0.7, 0.7) 
     
Interaction between 
ethnicity & linear 
duration 
    
Mixed-ethnicity   -16.2 (-32.4, -0.1) -16.1 (-32.2,- 0.1) 
Asian/Other   -2.4   (-13.6, 8.8) -2.4   (-13.6, 8.8) 
Pakistani   -27.7 (-40.8, -
14.5) 
-27.5 (-40.6, -14.3) 
Black   -9.5   (-26.3, 7.2) -10    (-26.7, 6.7) 
Not stated   1.7    (-10.7, 14) 1.5    (-10.8, 13.9) 
     





ethnicity & quadratic 
duration 
    
Mixed-ethnicity   13.9 (4.1, 23.8) 13.9 (4.1, 23.7) 
Asian/Other   2.1  (-4.6, 8.7) 2.2 (-4.5, 8.8) 
Pakistani   16.8  (8.8, 24.8) 16.7  (8.7, 24.8) 
Black   6       (-3.6, 15.6) 6.2    (-3.4, 15.8) 
Not stated   1.2   (-6.3, 8.6) 1.3    (-6.2, 8.8) 
     
Interaction between 
ethnicity & cubic 
duration 
    
Mixed-ethnicity   -2.3  (-4, -0.7) -2.3  (-4, -0.7) 
Asian/Other   -0.5  (-1.6, 0.6) -0.5  (-1.6, 0.6) 
Pakistani   -2.7  (-4.1, -1.3) -2.7  (-4.1, -1.3) 
Black   -1     (-2.6, 0.6) -1     (-2.6, 0.5) 
Not stated     











Model fit     
Aikake information 
criterion (AIC) 











-2LL 28710.04 28475.9 28431.42 28420.32 

















Figure 1A. Linear adjusted and predicted HbA1c trajectories by socioeconomic status (SES) 




Figure 1A Legend: 
 
  




Figure 1B. Linear adjusted and predicted HbA1c trajectories by ethnicity in 747 children and 
young people diagnosed with type 2 diabetes in England and Wales 
 
 
Figure 1B. Legend: 
 
 
